In our center from 1983 to 2010, 4221 patients were submitted to noninvasive and invasive cardiac studies, including a diagnostic EMB, because of clinically suspected myocarditis or nonischemic cardiomyopathies. In particular, 2396 (56.8%) underwent a biventricular EMB, 1153 (27.3%) underwent a selective LVEMB, and 672 (15.9%) underwent a selective RVEMB. Thus, among the 4221 Background-Use of left ventricular (LV) endomyocardial biopsy (EMB) to investigate cardiomyopathies is currently discouraged because it is considered riskier than and as contributive as right ventricular (RV) biopsy. The aim of our study is to report our experience with this option and to discuss its advantages and disadvantages. Methods and Results-In our center from 1983 to 2010, 4221 patients underwent diagnostic EMB. In particular, 2396 (56.8%) underwent biventricular EMB, 1153 (27.3%) underwent selective LVEMB, and 672 (15.9%) underwent selective RVEMB. The rate of complications and histological findings were retrospectively analyzed. The periprocedural major complication rate (perforation with or without cardiac tamponade, embolization) was 0.33% for LVEMB and 0.45% for RVEMB, with a significant decrease in the rate of major complications with time (from 1.6% and 1.9% in 1983-1988 to 0% and 0.3% in 2007-2013, respectively; P<0.001 for both), denoting a steep learning curve. No patients died. When the structural and functional abnormalities affected exclusively the LV, the diagnostic yield of LVEMB was 97.8% compared with 53% for RVEMB. Conversely, when the echocardiographic presence of increased wall thickness, local or global ventricular dilation, or dysfunction also involved the RV, the diagnosis was reached in 98.1% of LVEMBs and 96.5% of RVEMBs. This discrepancy was particularly evident for myocarditis, whereas in infiltrative and storage diseases, the histological abnormalities were always detectable in both ventricles. Conclusions-LVEMB is a safe procedure with very low transient complications, comparable to RVEMB. It appears diagnostically more contributive than RVEMB in patients with cardiomyopathies and clinically preserved RV. 
ndomyocardial biopsy (EMB) of the right ventricle (RV) and left ventricle (LV) was introduced into clinical practice in 1963 by Sekiguchi and Konno 1 and gradually became a recognized, valuable diagnostic investigation for primary myocardial diseases. Over the years, the development of new techniques such as immunohistochemistry, in situ hybridization, and polymerase chain reaction to detect a myocardial viral infection improved the diagnostic performance on EMB tissue. On the other hand, the development of new therapies for specific myocardial diseases, administrable on the basis of histological and molecular diagnosis, has given adjunctive value to the contribution of EMB.
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Despite the recognized diagnostic, prognostic, and therapeutic value of this procedure, recently described in a joint scientific statement, 2 the choice of the ventricular site of EMB is still a matter of question. Indeed, although EMB of the RV, approached by right internal jugular vein or femoral vein, is considered safe, the LV approach has not yet gained widespread acceptance because of concerns about possible more severe complications. Moreover, although the diagnostic advantage of a biventricular approach is widely recognized, 3 the diagnostic yield of LV versus RV biopsy is still unclear.
In the present single-center study, we report the experience of our group in a large population of patients over a 28-year period, analyzing retrospectively the incidence of complications and the diagnostic advantages of LVEMB.
Circulation
October 1, 2013 patients studied, 3549 (84%) received an LVEMB either selectively (1153 patients) or associated with an RVEMB (2396 patients) and constituted our patient population. Patients who received EMB to monitor heart transplantation were not included in the present study. Clinical indication for the EMB procedure was the evaluation of acute or chronic (>3 months) unexplained LV or RV dysfunction (LV ejection fraction ≤45%), unexplained ventricular arrhythmias, unexplained LV hypertrophy, cardiac masses, cardiac involvement in systemic diseases, and infiltrative or connective tissue disorders. 4 Furthermore, 34% of patients (n=1435) had 1 and 6% of patients (n=253) had ≥2 additional biopsies to monitor the evolution of the cardiac disease (ie, healing/healed or reactivation) or the response to a specific treatment (ie, immunosuppressive treatment for virusnegative inflammatory cardiomyopathy).
The decision to perform an isolated RVEMB or LVEMB was based on various clinical and technical considerations, including (1) elective involvement of a specific ventricular chamber (ie, RV in patients with suspected arrhythmogenic right ventricular dysplasia/cardiomyopathy); (2) extreme thinning of the RV or LV wall, increasing the risk of perforation; (3) older age with a difficult approach to the LV because of atherosclerotic lesions such as dolichomega aorta and femoral artery obstruction; (4) extreme height (>2 m or 6.56 ft) in patients in whom the long sheath and the bioptome length do not reach the LV; and (5) the presence of evident thrombotic apposition in the RV or LV chamber.
Cardiac Studies
All patients included in the study underwent clinical examination, chest x-ray, routine laboratory tests (including troponin, creatine phosphokinase, and creatine phosphokinase-MB), and noninvasive cardiac studies (resting ECG, Holter monitoring, echocardiography, and beginning in 2000 cardiac magnetic resonance). Invasive cardiac studies were performed after the patient provided written informed consent and approval was granted by the ethics committee of our institution and included cardiac catheterization, selective coronary angiography, biventricular, LV or RV angiography, and biventricular EMB, LVEMB, or RVEMB. Coronary angiography preceded the first EMB in all patients. EMB was performed in those patients without significant coronary stenosis or when the degree of cardiac dysfunction was not explained by the extent of coronary artery disease or ischemic damage. 5 Blood samples drawn at the time of cardiac catheterization were used for genetic, immunological, and molecular biology studies, and serological tests were used for the most common cardiotropic viruses. 6 
Endomyocardial Biopsy
EMBs were performed in the septal apical region of 1 or both ventricles and approached until 1990 with a King bioptome 7 and after 1990 by BIPAL biopsy forceps (Cordis Corp, East Bridgewater, NJ) using a 7F (501-613A Cordis) long sheath introduced from a right or left femoral access. The site of the biopsy was identified on a radiographic view using flashing of contrast medium. Three to 6 RV biopsies or 3 to 6 LV biopsies (from 2-5 mm 3 ) were drawn from each patient according to the clinical condition and the need for tissue samples. Control echocardiography was performed a few hours after the procedure to detect asymptomatic pericardial effusion. Further technical description of catheter-based LVEMB and RVEMB is given in the online-only Data Supplement.
EMB procedures were limited to 2 experienced operators. LVEMB was performed from 1983 to 1990 under heparinization (intravenous infusion of 2500 IU heparin). Beginning in 1990, patients were pretreated with aspirin 800 mg twice daily on the day preceding the examination and 800 mg before the procedure to reduce the thromboembolic risk without the administration of intravenous heparin. In cases in which the execution of EMB was not programmed and followed the evidence of normal coronary network, the EMB was preceded by intravenous infusion of 1 g aspirin. 8 Major complications included death, perforation with cardiac tamponade requiring pericardiocentesis, pericardial effusion not requiring pericardiocentesis, brain embolization with transient cerebral ischemia or stroke, pulmonary embolization, and permanent complete atrioventricular block. Minor complications included transient conduction disturbances, transient ventricular or supraventricular arrhythmias, transient chest pain, and intramyocardial hematoma. Local complications included vasovagal reaction, local nerve paresis, local hematoma, and femoral arterial-venous fistula.
Histopathological and Molecular Analyses
Tissue specimens were fixed in 10% buffered formalin and embedded in paraffin wax; 5-mm-thick sections were cut and stained with hematoxylin and eosin, Miller elastic van Gieson, and Masson trichrome and examined by light microscopy. Additional staining such as Congo red, periodic acid--Schiff, Sudan black, Pearl, Ziehl-Nielsen, and Giemsa was performed in patients with clinical suspicions of specific diseases. Additional samples were immediately frozen in optimum cutting temperature compound with isopentane cooled in liquid nitrogen and stored at −80°. For transmission electron microscopy, myocardial samples were fixed in 2% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.3) and embedded in Epon resin. Ultrathin sections were stained with uranyl acetate and lead hydroxide. Transmission electron microscopy was applied in patients with clinical suspicion of infiltrative or storage disease and in patients with the differential diagnosis of specific dilated cardiomyopathy (ie, toxic such as Adriamycin or hydroxyl-chloroquine cardiomyopathy). Idiopathic dilated cardiomyopathy was diagnosed in the absence of a secondary cause of cardiac dilation and dysfunction and in the presence at histology of nonspecific abnormal findings such as normally aligned myocardial fibers with nuclear evidence of hypertrophy and a normal or less-than-normal diameter (attenuation), degenerative changes in cardiomyocytes, increased interstitial and replacement fibrosis, and endocardial thickening.
The diagnosis of myocarditis was performed according to the Dallas criteria, confirmed beginning in 1990 by immunohistochemistry for the phenotypic characterization of the inflammatory infiltrates. 6 In particular, the presence of >14 infiltrating leukocytes per 1 mm 2 or the presence of >2 CD3-positive lymphocytes per highpower field (400-fold magnification), often adherent to the contour of cardiomyocytes, focally associated with cell necrosis, and depicted by fraying of sarcolemmal membrane, was considered diagnostic for active myocarditis. Beginning in 2000, 2 to 4 frozen myocardial specimens from each patient were used for polymerase chain reaction and reverse transcriptase--polymerase chain reaction analyses to detect cardiotropic DNA and RNA viruses (adenovirus, enterovirus, cytomegalovirus, parvovirus B19, influenza A and B viruses, herpes simplex viruses 1 and 2, human herpes virus 6, Epstein-Barr virus, hepatitis C virus). 6 Real-time polymerase chain reaction was not used for any of the viruses screened.
In the presence of a hypertrophied heart, a diagnosis of hypertrophic cardiomyopathy was reached in the presence of disarray of cardiomyocytes, consisting of short runs and interlacing myocardial fibers, as well as severe cell hypertrophy, bizarre-shaped nuclei, often surrounded by a clear zone (perinuclear halo), and increased myocardial fibrosis. Alternatively, the diagnosis of infiltrative (ie, amyloidosis) or storage (ie, Fabry disease, glycogenosis) disease manifesting with idiopathic LV hypertrophy was obtained by means of additional stainings (ie, Congo red for amyloidosis, Sudan black for Fabry disease, periodic acid--Schiff for glycogenosis) and electron microscopy. For the differentiation of the amyloid subtypes, immunohistochemistry for κ and λ immunoglobulin light chain, transthyretin, serum amyloid A protein, and apolipoprotein A-I was performed. Idiopathic restrictive cardiomyopathy was diagnosed in the presence of a hemodynamic restrictive pattern, with atrial enlargement and normally dimensioned ventricles associated with nonspecific histological findings (ie, cardiomyocyte hypertrophy, increased fibrosis).
The histological diagnosis of arrhythmogenic RV dysplasia/cardiomyopathy was based on international task force criteria 9 and beginning in 2010 on the revised criteria. 
Statistical Analysis

Results
Patient Characteristics
Baseline clinical and echocardiographic characteristics of the study patients are listed in Table 1 . In particular, 2804 patients had an ejection fraction <50%; among them, 757 (27%) suffered from acute-onset dilated cardiomyopathy and 2046 (73%) had a chronic (>3 months) form of cardiac dysfunction.
Complications of EMB
The rate of complications of LVEMB versus RVEMB was determined by comparing all patients of our population receiving an LVEMB (n=3549) and all patients submitted to an RVEMB (n=3068). The data are reported in Table 2 .
In particular, in all cases of LV perforation, there was a thin LV wall (maximal wall thickness, 7.5±1.3 mm) with LV dilation (72.5±8.7 mm) and LV dysfunction (20.3±3.3%). Brain embolization with transient cerebral ischemia, manifesting as visual or speech disturbances, resolved completely with mannitol and steroid administration. Importantly, most (n=5, 0.14%) of these events occurred before the instauration of pretreatment with aspirin. The 3 patients (0.08%) who experienced transient cerebral ischemia despite aspirin administration were affected by Fabry disease.
Globally, the major complication rate for LVEMB was 0.33% and for RVEMB was 0.45%, with no significant differences between the 2 EMB approaches (P=0.116). The overall major complication rate in our patient population was 0.39% (26 of 6617 procedures). The major complication rate for a biventricular EMB was 0.66% (16 of 2396) and for univentricular EMB was 0.54% (10 of 1825; P=0.172). Importantly, operator performance improved significantly with experience acquired over time. Indeed, a higher number (Table 2) , whereas local complications such as vasovagal reaction (1.3% in LVEMB versus 0.78% in RVEMB; P<0.05) and local hematoma (0.45% in LVEMB versus 0.19% in RVEMB; P<0.05) were significantly more frequent in the LV approach, although they were transient and did not require surgical repair.
Histopathological Diagnosis
The results of histopathology findings are reported in Table 3 . Histopathology showed abnormal changes compared with normal heart diagnostic or suggestive of a known disorder in 3448 patients (97.1%; Table 3 ). Among them, 1063 received an isolated LV biopsy (positive pathological diagnosis in 92.2%) and 2385 received a biventricular biopsy (positive pathological diagnosis in 99.5%). Thus, positive diagnostic EMB results were obtained more often in patients who received a biventricular EMB (P<0.001). This was related mainly to the reduced sampling error because on average 8.7±1.6 samples were taken per patient in those who underwent biventricular EMB compared with 4.4±1.4 samples in those who underwent selective LVEMB (P<0.001). On the basis of the initial clinical suspicion of disease, a failed diagnosis was observed mainly in patients with suspected myocarditis in the presence of preserved cardiac function (77 of 101, 76%) and occasionally in the presence of suspected hypertrophic cardiomyopathy (5 patients, 5%), idiopathic restrictive cardiomyopathy (5 patients, 5%), arrhythmogenic right ventricular dysplasia/ cardiomyopathy (5 patients, 5%), endomyocardial fibrosis (4 patients, 4%), amyloidosis (2 patients, 2%), tumor (2 patients, 2%), and connective tissue disease (1 patient, 1%). Thus, some diagnoses may be missed in both ventricles.
Myocarditis was the most frequent diagnosis (49.4%). Myocardial inflammation with either diffuse or focal signs of cardiomyocyte necrosis (ie, active myocarditis) was detected in 88% of patients and without these signs (borderline myocarditis) in 12% of patients. Most patients (95.5%) were affected by a lymphocytic myocarditis (CD45RO + , CD3 + , CD20 − ), whereas in 3.6%, an eosinophilic inflammatory process, including necrotizing vasculitis (Churg-Strauss disease), drug hypersensitivity, and Loeffler disease, was detected. In the remaining 0.9%, granulomatous myocarditis (sarcoidosis) and giant-cell myocarditis were observed (Figure 1) . Among the 1752 patients (49.4%) who globally received a diagnosis of myocarditis, 322 (18.4%) were diagnosed in the 7 years in which only the Dallas criteria were adopted, and 1430 (81.6%) were diagnosed in the 21 years after the introduction of immunohistochemistry, with an average of 46 diagnosis of myocarditis per year without immunohistochemistry and 68 myocarditis per year with immunohistochemistry, representing an overall 48%/y increase in the rate of diagnosis. In terms of duration of symptoms, 30% (n=526) had a recent onset (<3 months) and 70% (n=1226) had a chronic disease (>3 months). Polymerase chain reaction analysis revealed the presence of a viral infection in 28% of patients consisting of adenovirus (35%), Epstein-Barr virus (30%), enterovirus (16%), influenza A virus (5.2%), parvovirus B19 (3.3%), human herpes virus 6 (1.9%), hepatitis C virus (4.4%), and a combination of viruses (4.2%), showing a different distribution of viral genomes compared with recent series reported from some German centers. 3--12 Most patients with virus-negative inflammatory cardiomyopathy and ejection fraction <45% were treated with a combination of steroids (prednisone 1 mg·kg
) and azathioprine (50 mg twice daily) for at least 6 months, and most of them (>80%) showed a significant improvement of LV dimension and function paralleled by resolution of the inflammatory process. 6 Resolution of myocardial and vascular inflammation was usually obtained also in patients with giant-cell myocarditis, 13 granulomatous myocarditis, and Churg-Strauss disease 14 after high-dose steroids and immunosuppressive agents (azathioprine, cyclophosphamide).
In 22% of patients, the clinical and histological findings were suggestive of idiopathic dilated cardiomyopathy. In 8.3% of patients, dilated cardiomyopathy was associated with specific causes such as alcohol abuse, hormonal imbalance (ie, growth hormone deficiency, acromegaly, hyperthyroidism or hypothyroidism, pheochromocytoma, Cushing disease), drug toxicity (ie, cocaine, anagrelide, adriamycin, clozapine, hydroxychloroquine), nutritional deficiency (selenium/zinc deficiency in intestinal malabsorption and celiac disease), or dystrophinopathies (Duchenne and Becker diseases) and were defined as secondary dilated cardiomyopathies. From a pathological point of view, secondary dilated cardiomyopathy closely resembles idiopathic dilated cardiomyopathy, but the prevalence of peculiar pathological aspects could be detected in some cases. For instance, cell atrophy and extreme rarefying of contractile elements as a result of hyporegeneration (growth hormone deficiency) or hyperdegradation (Cushing disease) were detected in hormonal-imbalance dilated cardiomyopathy. In hypothyroidism, the interstitium was expanded by mucoid (periodic acid--Schiff positive) infiltration. On transmission electron microscopy, some forms of toxic dilated cardiomyopathy showed specific pathological findings. Anthracycline toxicity is characterized by a grading of lesions consisting mainly of the loss of myofibrillar content and vacuolization (Adria cells), distention of the sarcoplasmic reticulum, and extensive diffuse fibrosis. Hydroxichloroquine cardiomyopathy is characterized by the presence of intracytoplasmic vacuoles, consisting of concentric lamellar figures in single membrane-bound vesicles and curvilinear bodies. 15 Cocaine cardiomyopathy is characterized by supercontraction with rupture of sarcomeres. 16 As Figure 2 shows, 7.6% of patients received a histological diagnosis of hypertrophic cardiomyopathy Arrhythmogenic 
Comparison of LVEMB With RVEMB
To understand the diagnostic value of LVEMB compared with RVEMB, we concentrated on the 2396 patients who received a biventricular EMB (Table 4) . In all patients, the average numbers of specimens drawn from LV and RV chamber were comparable (4.5±1.2 from the LV versus 4.2±1.6 from the RV; range, 3-6 samples per chamber).
LVEMB showed diagnostic histopathological findings in 96.3% of cases (2307 patients), whereas RVEMB showed diagnostic histopathological findings in 71.4% (1711 patients; P<0.001).
To assess the diagnostic value of LVEMB versus RVEMB in relation to the evidence of a structural and functional abnormality of the biopsied chamber, we retrospectively analyzed the presence at echocardiography of increased wall thickness, local or global ventricular dilation, and local or global hypokinesia. The presence of at least 1 of these parameters was considered indicative of chamber involvement by the pathological process (Table 5) .
Combining the histopathology results with the echocardiography data, we observed that when the structural or functional abnormality affected the LV exclusively or predominantly, the diagnostic yield of LVEMB increase to 97.8% and the diagnostic yield of RVEMB decreased to 53% (P<0.001; Figure 3) . Thus, omitting LVEMB in these patients would have resulted in missing 47% of the diagnoses (Figure 3) . Conversely, if the RV was also structurally or functionally involved by the disease, the diagnosis was reached in 98.1% of LVEMB and 96.5% of RVEMB, so omitting the LVEMB in this group would have resulted in missing only 3.5% of the diagnoses.
Discussion
This study represents the largest contribution on procedural safety and diagnostic value of LVEMB in patients with cardiomyopathies. A total of 4222 patients were biopsied in a 28-year period in a single center. Among them, 3549 received an LVEMB, either selectively or associated with an RVEMB.
Safety of LVEMB
In our experience, the incidence of major complications after LVEMB was very low (0.33%) and comparable to that of RVEMB (0.45%), suggesting that a biopsy in the LV is as safe as in the RV. Remarkably, no patients died. These results are at variance with a recent report by Yilmaz et al 3 and are likely related to a greater operator experience obtained over a longer period of time.
In particular, LVEMB showed a lower incidence of cardiac perforation compared with RVEMB (P=0.046), most likely because of the thinner RV wall. Indeed, in all LV perforations, there was a thin LV wall associated with remarkable ventricular dilation.
The second major complication of LVEMB was brain embolization (0.24%). Importantly, this complication was associated with transient cerebral ischemia and no permanent damage and was significantly reduced when patients were pretreated with high-dose aspirin. Notably, the 3 patients reporting cerebral ischemia despite this pretreatment were affected by Fabry disease in which endocardial fat exposition in addition to a recognized platelet hyperactivity could have overcome the effect of aspirin. No heparin infusion was adopted during the procedure, except in case of thromboembolic events.
The low complication rate in our study may also be related to the high level of experience of a few operators dedicated to the execution of EMB in our center. A higher rate of complications from EMB was reported in previous studies 17, 18 in which the procedure was performed in >1 center or by a high number of operators, and an even lower incidence of EMB complications was present when only a small number of interventional cardiologists with extensive experience with the EMB procedure (>100 EMB procedures per year) were operating. 19 In the present study, the 2 operators' ability improved significantly with experience, and a steep learning curve was clearly identified with a complication rate that was 2.5 fold higher in the first 7 years than in the following 10 years and 17 times higher than in last decade.
Diagnostic Impact of LVEMB
EMB showed abnormal changes diagnostic of or compatible with a known disorder in a high number of patients, and biventricular EMB showed a major diagnostic yield compared with isolated LVEMB (99.5% and 92.2%, respectively). This finding confirms the results of a recent study by Yilmaz et al, 3 being related mainly to the reduced sampling error resulting from the higher number of specimens available. Indeed, the lack of a histopathological diagnosis in 7.8% of patients who received an isolated LVEMB was related mainly to an inadequate amount of tissue available (1-2 samples of small dimensions, ie, <2 mm 3 ). Thus, a biventricular approach is generally advisable because it does not increase the overall periprocedural risks (0.5% for biventricular EMB and 0.44% for univentricular EMB). At variance with the Yilmaz et al 3 series, our study showed a higher rate of diagnostic biopsies (99.5% biventricular diagnostic yield compared with 79.3% in the Yilmaz et al series). This can be related to a more extensive indication for EMB in patients with idiopathic LV hypertrophy, in whom the diagnostic yield of EMB in differentiating hypertrophic cardiomyopathy from secondary forms of LV hypertrophy (ie, infiltrative and storage diseases) is almost 100%. In addition, because our center is a tertiary referral center for the diagnosis of myocarditis, many patients with high pretest probability for myocardial inflammation (ie, clinical history, positive cardiac magnetic resonance) were sent to our department for a definite diagnosis and personalized treatment, which can explain the high diagnostic rate for myocarditis. Finally, compared with the Yilmaz et al article, our study reports a larger population biopsied over a longer period and emphasizes the safety and diagnostic yield of EMB. When the patient's clinical condition requires reducing the length of the procedure, it is important for the operator to make a correct decision as to which ventricular approach is more likely to reach a histological diagnosis. For this reason, we compared the diagnostic accuracy of LVEMB and RVEMB in patients who received a biventricular EMB and demonstrated that the overall diagnostic yield of LVEMB was higher than that of RVEMB (96.3% and 71.4%, respectively; P<0.001).
This discrepancy was even more evident when structural or functional echocardiographic abnormalities affected the LV exclusively; the diagnostic yield of LVEMB increased to 97.8% and the diagnostic yield of RVEMB decreased to 53%. Thus, omitting LVEMB in these patients would have resulted in missing 47% of the histological diagnoses. Indeed, LV was the only chamber imaged in 66.5% of our cases.
Myocarditis was associated with echocardiographic LV involvement in 94.2% of cases, alone in 67% and in association with RV in 26.9%. In patients with isolated LV echocardiographic involvement, the histological and immunohistochemical diagnosis of myocardial inflammation was present in 95.7% of LVEMB and in 54.2% of RVEMB, whereas in patients with associated echocardiographic RV involvement, the LVEMB was diagnostic in 96.6% of cases and the RVEMB was diagnostic in 96.1%. Thus, in the clinical suspicion of myocarditis, when both ventricles show echocardiographic abnormalities, the EMB can be performed indifferently in the LV or RV, whereas in the presence of selective LV involvement, an LVEMB is advisable.
In idiopathic dilated cardiomyopathy, the LV was always involved by the disease at echocardiography (100%), whereas the RV was affected in 29.5% of patients. Histology showed pathological changes in 100% of LVEMB and in 48.3% of RVEMB (P<0.001) when the RV was not involved at imaging. The percentage rose to 98.8% when the RV showed echocardiographic abnormalities. Although the histological findings are nonspecific, EMB diagnosis of idiopathic dilated cardiomyopathy may be valuable in the workup of heart failure to exclude specific diseases, including myocarditis. The distinction between these 2 pathological entities is crucial because a diagnosis of idiopathic dilated cardiomyopathy can direct the clinician to a more radical therapeutic option (ie, heart transplantation), whereas in myocarditis, a specific etiologic treatment can be taken under consideration. On the other hand, recent studies showed that cardiac magnetic resonance imaging is unsatisfactory for guiding clinical management of patients presenting with chronic heart failure. 20 Progressive heart failure can also be caused by secondary forms of dilated cardiomyopathy (eg, alcoholism, hormonal imbalance, dystrophinopathies, toxicity, and nutritional deficiency). Even in this setting, the LV appears clinically and histologically more compromised than the RV, and the tissue obtainable from an LV biopsy can be used for research purposes to assess myocardial trace elements 21 and enzyme activity 15 and to recognize the effects of hormonal imbalances. 22 Thus, in our experience, the LV seems the preferential site to perform an EMB when idiopathic or secondary dilated cardiomyopathy is clinically suspected, whereas the RV should be considered an alternative option when it would be dilated or hypokinetic.
The use of LVEMB in patients with unexplained LV hypertrophy is still controversial, and it is generally recommended when an infiltrative or storage disease is suspected and noninvasive tests are inconclusive. 2 Indeed, clinical presentation of some infiltrative diseases can be misleading because of normal QRS voltages or the presence of LV bundle-branch block on ECG, whereas some storage diseases like Fabry and Danon disease or mutation of the PRKAG2 gene, particularly in sporadic form, may inextricably mimic an obstructive, nonobstructive, and even apical hypertrophic cardiomyopathy. Gene analysis can be diagnostic but expensive and time consuming and can miss new or unknown gene mutations. In this situation, EMB can be extremely useful. In our experience, in up to 18% of hypertrophic cardiomyopathy clinical diagnoses, EMB unexpectedly allowed reclassification of patients affected by infiltrative or storage myocardial disease. 23 In patients with true hypertrophic cardiomyopathy, LVEMB can be specifically useful in analyzing the cause of cardiac deterioration, 24 in showing the histological changes of the disease that are unreliable in the highly trabeculated RV myocardium, and in providing myocardial tissue for research purposes.
Conclusions
LVEMB is a safe diagnostic procedure with very low, transient complications comparable to those of RVEMB. It seems diagnostically more contributive than RVEMB when cardiomyopathy is associated with normal or poorly compromised RV. 
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CLINICAL PERSPECTIVE
Endomyocardial biopsy (EMB) has a recognized and increasing role in the diagnosis, prognosis, and treatment of myocarditis and other nonischemic cardiomyopathies. However, the risk of complications still limits its use, particularly when a left ventricular (LV) approach is considered. In the present single-center study, over a 28-year period, 3549 patients received an LVEMB either selectively (n=1153) or associated with a right ventricular (RV) EMB (n=2396), and 672 patients received an isolated RV biopsy. We retrospectively analyzed the incidence of complications and the diagnostic advantages of LVEMB versus RVEMB. Biopsies were performed via the femoral approach by 2 experienced operators. The patients were treated with high-dose aspirin before the procedure to prevent thromboembolic risk. The EMB samples were processed with stateof-the-art histological, immunohistochemical, molecular biology, and electron microscopy techniques. The major complication rate was 0.33% for LVEMB and 0.45% for RVEMB with a significant decrease with time, denoting a steep learning curve for the operators. No patient died. EMB showed abnormal specific and nonspecific changes in 97% of patients, and biventricular EMB showed a major diagnostic yield compared with isolated LVEMB. When the structural and functional abnormalities affected the LV exclusively, the diagnostic yield of LVEMB significantly increased compared with RVEMB, whereas it was comparable when the RV was also involved. Thus, LVEMB appears to be as safe as RVEMB and diagnostically more contributive when a cardiomyopathy is associated with a normal RV. Experienced operators can guarantee a safe procedure even with an LV approach. EMB while a long sheath with straight tip was introduced through the femoral artery and used for left ventricular EMB. Biopsy specimens were taken using a disposable dedicated cardiac bioptome.
SUPPLEMENTAL MATERIAL
The cardiac biopsy forceps used has a PTFE-covered shaft with a length of 104 cm for curving the distal section of the forceps into the desired shape and to direct it easily towards the ventricular wall and two stainless steel symmetrical hinged cutting jaws able to drawn a 5.2 mm 3 of tissue sample.
The BIPAL biopsy forceps has a great operational flexibility having at its proximal end a 3-pull ring handle with spring so that samples can be held easily while being removed and the central ring of the handle rotates to accommodate any hand position.
The left ventricular EMB procedure starts with a 7F pigtail guiding catheter that is introduced into the long sheath and then passed retrogradely through the aortic valve into the left ventricle using a standard J tip guide wire. Once the sheath is positioned near to the segment of the left ventricle where the biopsy should be performed the guiding catheter is withdrawn through the sheath. Before insertion the bioptome is bent smoothly in its distal part to enhance flexibility and to decrease the risk of perforation. Then the bioptome is advanced through the guiding sheath into the left ventricle under biplane fluoroscopic control (30° RAO and 60° LAO) which helps to guide the tip of the catheter to the target area. The site of the biopsy is identified on a radiographic view using flashing of contrast medium. Care is taken that the jaws of the bioptome are opened within the left ventricular cavity before close wall contact is reached. A series of ventricular premature beats usually denote the contact with the ventricular wall. Then a soft pressure is exerted and the biopsy specimen is taken from the wall region of interest. After each biopsy, aspiration of blood from the sheat and rinsing with heparinised saline solution is performed to prevent clotting.
For right ventricular biopsy, a 7F pigtail guiding catheter inserted into the sheath with angulated tip is advanced over a J tip guide wire into the right ventricle. Under fluoroscopic control at 30° RAO the tip of the guiding catheter is positioned in the septal position. Then the guiding catheter is withdrawn through the sheath, the bioptome is advanced and the biopsies are taken from the septum. In addition to using the preshaped sheath the bioptome is usually manually bend in the distal part by 30°-45°, so that the jaws can be orientated more directly toward the septum.
Both the procedures were performed after intravenous infusion of 2.500 IE heparin from 1983 to 1990 but later heparin was only used in the washing saline solution since the patients were pretreated with aspirin 800 mg bidie the day preceding the exam and 800 mg before the procedure.
